industry's need for speed. Dash Bio is tackling this bottleneck head-on. The company has built the first highly automated, GLP-compliant bioanalysis lab purpose-built to eliminate the friction of traditional CROs. Dash delivers assays like ELISA,...
Products Administration (NMPA) has approved mazdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, for chronic weight management in Chinese adults with overweight or obesity. Mazdutide is the world's first...
to identify high-risk patient groups that may benefit the most from interventions that preserve lean muscle mass during GLP-1 treatment for diabetes, weight loss, and chronic weight management. In keeping with FDA’s recent draft Guidance on using...
cells in clinical trials for refractory cancers; and HFG1, derived from its tLNPplex™ platform, for mRNA expression of a GLP-1R agonist for weight loss and diabetes. For more information please visit https://highfieldbio.com/.
CordenPharma provides development and manufacturing services for clinical and commercial demand of Viking Therapeutics' GLP-1 drug candidate VK2735, a Dual GLP-1/GIP Receptor Agonist, across the full supply chain from drug substance to drug product...
Global Business Units, Healthcare, at Jabil. Jabil is a leader in parenteral drug delivery, in support of markets like GLP-1s. This acquisition will significantly enhance Jabil’s existing Pharmaceutical Solutions offering, which includes the...
Eden has launched the world's first compounded semaglutide gummy. Designed to deliver the benefits of GLP-1 medications in a convenient, needle-free format, this innovative format reimagines how individuals approach GLP-1 programs in the United...
(FIC), tri-specific agonist targeting Fibroblast growth factor 21 receptor (FGF21R), Glucagon-like peptide-1 receptor (GLP-1R), and Glucagon receptor (GCGR) has completed the dosing of the first patient in the Phase 2 study of DR10624 for the...
oral testosterone treatment for men. Together, they aim to conduct a pioneering study that will measure the impact of GLP-1s on muscle mass in male patients using the treatment for weight loss. In conjunction with muscle mass reduction being a...
The molecular design strategy and experimental results of Bright Gene's dual GLP-1/GIP receptor agonist, BGM0504, have been published online in Scientific Reports, a sub-journal of Nature, on July 19, 2024. Bright Gene (Stock Code: 688166.SH) is...
